Abstract
Disruptions to the hemostatic pathway can cause a variety of serious or even life-threatening complications. Situations in which the coagulation of blood has become disturbed necessitate immediate care. Thrombin-binding aptamers are single-stranded nucleic acids that bind to thrombin with high specificity and affinity. While they can effectively inhibit thrombin, they suffer from rapid degradation and clearance in vivo. These issues are resolved, however, by attaching the therapeutic aptamer to a nucleic acid nanostructure. The increased size of the nanostructure-aptamer complex elongates the post-infusion half-life of the aptamer. These complexes are also immunoquiescent. A significant benefit of using nucleic acids as anticoagulants is their rapid deactivation by the introduction of a nanostructure made fully from the reverse complement of the therapeutically active nanostructure. These advantages make nanoparticle conjugated antithrombin aptamers a promising candidate for a rapidly reversible anticoagulant therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ke W, Chandler M, Cedrone E, Saito RF, Rangel MC, De Souza JM et al (2022) Locking and unlocking thrombin function using Immunoquiescent nucleic acid nanoparticles with regulated retention in vivo. Nano Lett 22(14):5961–5972
Panigaj M, Johnson MB, Ke W, McMillan J, Goncharova EA, Chandler M et al (2019) Aptamers as modular components of therapeutic nucleic acid nanotechnology. ACS Nano 13(11):12301–12321
Dupont DM, Thuesen CK, Bøtkjær KA, Behrens MA, Dam K, Sørensen HP et al (2015) Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites. PLoS One 10(3):e0119207
Krissanaprasit A, Key CM, Froehlich K, Pontula S, Mihalko E, Dupont DM et al (2021) Multivalent aptamer-functionalized single-strand RNA origami as effective, target-specific anticoagulants with corresponding reversal agents. Adv Healthc Mater 10(11):2001826
Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC (2008) A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 6(5):789–796
Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M et al (2006) First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology. Circulation 114(23):2490–2497
Woodruff RS, Sullenger BA (2015) Modulation of the coagulation Cascade using aptamers. Arterioscler Thromb Vasc Biol 35(10):2083–2091
Becker R, Povsic T, Cohen MG, Rusconi C, Sullenger B (2010) Nucleic acid aptamers as antithrombotic agents: opportunities in extracellular therapeutics. Thromb Haemost 103(3):586–595
Zavyalova E, Samoylenkova N, Revishchin A, Golovin A, Pavlova G, Kopylov A (2014) Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model. PLoS ONE 9(9):e107113
Mayer G, Rohrbach F, Pötzsch B, Müller J (2011) Aptamer-based modulation of blood coagulation. Hamostaseologie 31(04):258–263
Vaganov AA, Taranushenko TE, Luzan NA, Shchugoreva IA, Kolovskaya OS, Artyushenko PV et al (2022) Aptamers regulating the hemostasis system. Molecules 27(23):8593
Gahlon HL, Sturla SJ (2013) Hydrogen bonding or stacking interactions in differentiating duplex stability in oligonucleotides containing synthetic nucleoside probes for alkylated DNA. Chem Eur J 19(33):11062–11067
Afonin KA, Viard M, Koyfman AY, Martins AN, Kasprzak WK, Panigaj M et al (2014) Multifunctional RNA nanoparticles. Nano Lett 14(10):5662–5671
Zadeh JN, Steenberg CD, Bois JS, Wolfe BR, Pierce MB, Khan AR et al (2011) NUPACK: analysis and design of nucleic acid systems. J Comput Chem 32(1):170–173
Kretz CA, Stafford AR, Fredenburgh JC, Weitz JI (2006) HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by Prothrombinase. J Biol Chem 281(49):37477–37485
Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ (1992) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355(6360):564–566
Di Cera E (2008) Thrombin. Mol Asp Med 29(4):203–254
Potter TM, Rodriguez JC, Neun BW, Ilinskaya AN, Cedrone E, Dobrovolskaia MA (2018) In vitro assessment of nanoparticle effects on blood coagulation. Methods Mol Biol 1682:103–124
Lakna: difference between intrinsic and extrinsic pathways in blood clotting. https://pediaa.com/difference-between-intrinsic-and-extrinsic-pathways-in-blood-clotting/ (2018)
STart4 standard operating procedure and training manual. Diagnostica Stago(June 2002)
HHS FDA/CDER/CVM. Bioanalytical method validation. Guidance for industry
Largy E, Mergny J-L, Gabelica V (2016) Role of alkali metal ions in G-quadruplex nucleic acid structure and stability. Springer, Cham, pp 203–258
Acknowledgments
Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM139587 (to K.A.A.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rolband, L.A., Ke, W., Afonin, K.A. (2023). Aptamer Conjugated RNA/DNA Hybrid Nanostructures Designed for Efficient Regulation of Blood Coagulation. In: Afonin, K.A. (eds) RNA Nanostructures. Methods in Molecular Biology, vol 2709. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3417-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3417-2_19
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3416-5
Online ISBN: 978-1-0716-3417-2
eBook Packages: Springer Protocols